Novartis
Novartis' Targeted Radio-Ligand Therapy Highlighted at ASCO as Potential New mCRPC Option
The treatment combined with standard-of-care therapies lowered the risk of death by 38 percent in PSMA-positive, refractory prostate cancer patients.
Novartis On Track to Pursue Kymriah Approval in Follicular Lymphoma After Promising Results
The firm announced positive data from the Phase II ELARA trial and said it will seek regulatory approval for the CAR T-cell therapy in refractory follicular lymphoma.
AACR Project GENIE Enables Analysis of Growing Actionability, Disparities in Precision Oncology
Premium
At the annual meeting, researchers demonstrated how the growing real-world database can be useful in answering myriad research questions.
Novartis Targeted Radioligand Therapy Prolongs Survival for PSMA-Positive mCRPC Patients
The company plans to file for regulatory approval for 177Lu-PSMA-617 this year, which met primary endpoints in the Phase III VISION study.
Drugmakers Join Vineti to Promote Enhanced Standards for Personalized Cell Therapies
The first project is a proposal to advance a digital ID badge for tracking cell therapies from manufacturing, through shipment, to patient delivery.